Tumors: key molecular mechanism in therapy resistance identified.
Posted by giorgiobertin on June 8, 2023
A research conducted by the study group on genome stability at the Mechanisms, Biomarkers and Models department of the ISS Environment and Health Department, just published in Nucleic Acids Research, has identified a new molecular mechanism which, in BRCA-deficient tumor cells, determines the onset of resistance to treatment with PARP inhibitors; one of the targeted therapies widely used for the treatment of breast and ovarian cancers, but more recently also of the prostate.
Recall that mutations in BRCA1, BRCA2 and other BRCA genes characterize hereditary breast and ovarian cancer. However, mutations in BRCA and homologous recombination-related genes have also been found in subsets of sporadic breast cancers and, recently, also in prostate cancers.
The discovery could lead in the future to define new therapeutic options capable of countering treatment resistance, as well as to the development of a biomarker to identify patients who would respond poorly to PARP inhibitors.
Read the full text of the article:
Phosphorylation status of MUS81 is a modifier of Olaparib sensitivity in BRCA2-deficient cells.
Blandino F , Malacaria E , Figlioli C , Noto A , Pugliese GM , Franchitto A , Pichierri P .
Nucleic Acids Res. 2023 May 31:gkad470. doi: 10.1093/nar/gkad470. Epub ahead of print. PMID: 37254810.
This entry was posted on giugno 8, 2023 a 5:12 PM and is filed under News-ricerca.
Contrassegnato da tag: biochimica, genetica, oncologia. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, oppure trackback from your own site.